6998 — Genor Biopharma Holdings Share Price
0.000.00%
Last trade - 00:00- HK$1.09bn
- -HK$38.41m
- CNY206.23m
- 15
- 19
- 85
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.88 | ||
| Price to Tang. Book | 0.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.21% | ||
| Return on Equity | -4.38% | ||
| Operating Margin | -35.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 10.33 | n/a | 15.93 | n/a | 206.23 | 333.58 | n/a | 73.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genor Biopharma Holdings Ltd is a company primarily engaged in the biopharmaceuticals business. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include GB491 (Lerociclib), GB261, GB263T and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its business in the domestic market.
Directors
- Feng Guo CHM (51)
- Joe Xin Hua Zhou PRE (67)
- Qiyong Hu CFO (47)
- Wende Chen COO (57)
- Steven Ziyi Kan CTO (58)
- Yao Chen VPR (47)
- Huiyang Cheng VPR (45)
- Jun Lin VPR (36)
- Qingtang Duan OTH (39)
- Tong Li OTH (51)
- Siu Pik Ho SEC
- Yu Chen NED (39)
- Dong Lyu NED (46)
- Lin Ni NED (46)
- Wen Chen NID (52)
- Edwin Fung NID (55)
- Honghao Zhou NID (81)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 10th, 2017
- Public Since
- October 7th, 2020
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 520,358,899
- Address
- 89 Nexus Way, Camana Bay,, SHANGHAI, 201203
- Web
- https://www.genorbio.com/
- Phone
- +86 2161690700
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 6998
Similar to 6998
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Genor Biopharma Holdings share price?
As of Today at 20:48 UTC, shares in Genor Biopharma Holdings are trading at HK$2.07. This share price information is delayed by 15 minutes.
How has the Genor Biopharma Holdings share price performed this year?
Shares in Genor Biopharma Holdings last closed at HK$2.07 and the price had moved by +65.6% over the past 365 days. In terms of relative price strength the Genor Biopharma Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +67.49% over the past year.
What are the analyst and broker recommendations for Genor Biopharma Holdings?
The overall consensus recommendation for Genor Biopharma Holdings is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genor Biopharma Holdings dividend yield?
Genor Biopharma Holdings does not currently pay a dividend.
Does Genor Biopharma Holdings pay a dividend?
Genor Biopharma Holdings does not currently pay a dividend.
When does Genor Biopharma Holdings next pay dividends?
Genor Biopharma Holdings does not currently pay a dividend.
How do I buy Genor Biopharma Holdings shares?
To buy shares in Genor Biopharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genor Biopharma Holdings?
As of the previous close price of HK$2.07, shares in Genor Biopharma Holdings had a market capitalisation of HK$1.09bn.
Where are Genor Biopharma Holdings shares listed?
Here are the trading details for Genor Biopharma Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6998
What kind of share is Genor Biopharma Holdings?
Based on an overall assessment of its quality, value and momentum Genor Biopharma Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genor Biopharma Holdings share price forecast for 2025?
The analyst consensus target price for shares in Genor Biopharma Holdings is HK$1.46. That is 29.41% below the last closing price of HK$2.07.
Analysts covering Genor Biopharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.38 for the next financial year.
Find out moreWhat is the trend in the Genor Biopharma Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genor Biopharma Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +8.59%.
As of the last closing price of HK$2.07, shares in Genor Biopharma Holdings were trading +22.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genor Biopharma Holdings PE Ratio?
The Genor Biopharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genor Biopharma Holdings?
Genor Biopharma Holdings' management team is headed by:
- Feng Guo - CHM
- Joe Xin Hua Zhou - PRE
- Qiyong Hu - CFO
- Wende Chen - COO
- Steven Ziyi Kan - CTO
- Yao Chen - VPR
- Huiyang Cheng - VPR
- Jun Lin - VPR
- Qingtang Duan - OTH
- Tong Li - OTH
- Siu Pik Ho - SEC
- Yu Chen - NED
- Dong Lyu - NED
- Lin Ni - NED
- Wen Chen - NID
- Edwin Fung - NID
- Honghao Zhou - NID